Stanley Druckenmiller at CNBC’s Delivering Alpha on Sept. 28, 2022.
Scott Mlyn | CNBC
A model of this text first appeared in CNBC’s Inside Wealth publication with Robert Frank, a weekly information to the high-net-worth investor and shopper. Join to obtain future editions, straight to your inbox.
Funding corporations of ultra-wealthy households are serving to gas the enterprise capital rebound in biotechnology. In August, household workplaces made 52 direct investments in non-public firms, with biotech startups representing about 20% of transactions, in accordance with knowledge supplied completely to CNBC by Fintrx, a non-public wealth intelligence platform.
Stanley Druckenmiller’s Duquesne Household Workplace, one of many most lively household workplaces within the U.S., has backed at the least 4 prescription drugs or life sciences firms this 12 months, in accordance with Fintrx. Final month, Duquesne participated in a $90 million Collection C spherical for Epicrispr Biotechnologies. The 8-year-old startup is pioneering a brand new gene remedy for a uncommon muscle dysfunction referred to as facioscapulohumeral muscular dystrophy, or FSHD.
Druckenmiller mentioned in January that Duquesne had made substantial investments in biotech because of the potential of synthetic intelligence.
“I knew as a result of I have been on the board of Memorial Sloan Kettering for 30 years, that most likely the perfect use case on the market of AI is biotech via drug discovery, diagnostics, monitoring every little thing,” he mentioned in an interview carried out by Morgan Stanley.
In August, the namesake household workplace of Jeff Bezos additionally joined a $188 million Collection E for LifeMine Therapeutics, which makes use of AI to research fungal genomes to develop new medication. LifeMine is at present testing a drug compound to forestall organ failure in transplant recipients.
Invoice Gates‘ enterprise capital agency, Gates Frontier, additionally participated within the megaround.
Enterprise funding for biotechnology has rebounded strongly this 12 months. U.S. and European biopharma startups raised a whopping $12.6 billion within the first half of 2026, a five-year excessive, in accordance with evaluation by Silicon Valley Financial institution, now a division of First Residents Financial institution after its 2023 collapse and subsequent sale.
That mentioned, buyers are writing fewer checks general, particularly for early-stage startups, with a better share of funding going towards firms with medication already in testing, in accordance with SVB’s evaluation, citing its personal knowledge and knowledge from PitchBook.